DRUG THERAPY FOR PATIENTS WITH MENTAL DISORDERS WHO HAVE A CORONAVIRUS INFECTION (COVID-19)

The article describes the features of drug therapy for patients with mental disorders who have a coronavirus infection (COVID-19). These questions are extremely relevant for practicing Russian psychiatrists at the moment, since according to data from China and Italy during the epidemic, psychiatric patients were more vulnerable to its spread than the healthy population, and had a higher risk of severe disease and complications. The article discusses the reasons for the greater vulnerability of this group of patients to the spread of infection. Based on the literature analysis, data on possible drug interactions between psychotropic drugs and drugs used for the treatment of patients with coronavirus infection are presented. Special attention is paid to adverse reactions that may occur in patients with hyperthermia, respiratory and heart failure when using psychotropic drugs, as well as tactics for relieving psychomotor agitation. Recommendations are given for the treatment of patients with mental pathology and COVID-19, include correction of dosages of psychotropic drugs, the use of drugs with minimal side effects, consideration of possible adverse drug interactions, careful monitoring of the somatic state of patients.